Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. [electronic resource]
Producer: 20200608Description: 35-40 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Cell Differentiation
- Compassionate Use Trials
- Disease Progression
- Female
- Humans
- Iodine Radioisotopes -- therapeutic use
- Italy
- Male
- Middle Aged
- Patient Safety
- Phenylurea Compounds -- adverse effects
- Progression-Free Survival
- Protein Kinase Inhibitors -- adverse effects
- Quinolines -- adverse effects
- Radiation Tolerance
- Radiopharmaceuticals -- therapeutic use
- Retrospective Studies
- Risk Factors
- Thyroid Neoplasms -- drug therapy
- Time Factors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.